Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): AnAASLC phase II trial
Autore:
Krajnik, G; Mohn-Staudner, A; Thaler, J; Greil, R; Schmeikal, S; Marhold, F; Deutsch, J; Preiss, P; Malayeri, R; Schafer-Prokop, C; Wein, W; Huber, H; Pirker, R;
Indirizzi:
Univ Vienna, Dept Internal Med 1, Div Oncol, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 d 1, Div Oncol, A-1090 Vienna, Austria Pulmol Zentrum, Vienna, Austria Pulmol Zentrum Vienna AustriaPulmol Zentrum, Vienna, Austria Innsbruck Univ, Dept Internal Med, A-6020 Innsbruck, Austria Innsbruck Univ Innsbruck Austria A-6020 l Med, A-6020 Innsbruck, Austria LKH, Grimmenstein, Austria LKH Grimmenstein AustriaLKH, Grimmenstein, Austria LKH, Klagenfurt, Austria LKH Klagenfurt AustriaLKH, Klagenfurt, Austria LKH, Waidhofen An Der Thaya, Austria LKH Waidhofen An Der Thaya AustriaLKH, Waidhofen An Der Thaya, Austria Univ Vienna, Dept Radiol, Vienna, Austria Univ Vienna Vienna AustriaUniv Vienna, Dept Radiol, Vienna, Austria Eli Lilly & Co, Vienna, Austria Eli Lilly & Co Vienna AustriaEli Lilly & Co, Vienna, Austria
Titolo Testata:
ANNALS OF ONCOLOGY
fascicolo: 8, volume: 11, anno: 2000,
pagine: 993 - 998
SICI:
0923-7534(200008)11:8<993:VIANLC>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLUS CISPLATIN; STAGE-IIIB; PACLITAXEL-CISPLATIN; SYMPTOM RELIEF; MITOMYCIN-C; COMBINATION; IV; CHEMOTHERAPY; VINBLASTINE; ETOPOSIDE;
Keywords:
chemotherapy; gemcitabine; non-small-cell lung cancer; phase II trial; vinorelbine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
44
Recensione:
Indirizzi per estratti:
Indirizzo: Pirker, R Univ Vienna, Dept Internal Med 1, Div Oncol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria Univ Vienna Wahringer Gurtel 18-20 Vienna Austria A-1090 ustria
Citazione:
G. Krajnik et al., "Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): AnAASLC phase II trial", ANN ONCOL, 11(8), 2000, pp. 993-998

Abstract

Purpose: The purpose of the present phase II trial was to determine the efficacy and toxicity of vinorelbine-gemcitabine in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: From December 1997 to February 1999, 78 chemotherapy-naive patients (median age 60 years, Karnofsky performance status of 100, 90, 80 and 70 present in 5%, 41%, 36% and 18% of the patients, respectively) with stage IIIB (17%) or IV (83%) NSCLC (65% adenocarcinomas, 22% squamous-cell carcinomas, 10% large-cell carcinomas, 3% mixed-cell carcinomas) received 25 mg/m(2) vinorelbine and 1200 mg/m(2) gemcitabine on days 1, 8 and 15 of a four-week cycle. Results: In an intent-to-treat analysis, partial responses were seen in 19% of the patients. The median duration of response was 4.4 months. The median survival time was seven months and the one-year survival rate was 32%. Myelosuppression was the main side effect with WHO grade 3/4 neutropenia andthrombocytopenia in 35% and 11% of the patients, respectively. Other side effects were usually mild to moderate. Conclusions: Vinorelbine-gemcitabine is active, well tolerated and easy toadminister on an outpatient basis in advanced NSCLC. Thus a randomized comparison of this combination with platinum-based protocols is warranted in patients with advanced NSCLC.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/07/20 alle ore 08:54:41